EA202091015A1 - Новый т-клеточный рецептор - Google Patents

Новый т-клеточный рецептор

Info

Publication number
EA202091015A1
EA202091015A1 EA202091015A EA202091015A EA202091015A1 EA 202091015 A1 EA202091015 A1 EA 202091015A1 EA 202091015 A EA202091015 A EA 202091015A EA 202091015 A EA202091015 A EA 202091015A EA 202091015 A1 EA202091015 A1 EA 202091015A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tcr
cell
clone
vector
agent
Prior art date
Application number
EA202091015A
Other languages
English (en)
Russian (ru)
Inventor
Эндрю Сьюэлл
Гарри Долтон
Original Assignee
Юниверсити Коллидж Кардифф Консалтентс Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Коллидж Кардифф Консалтентс Лтд filed Critical Юниверсити Коллидж Кардифф Консалтентс Лтд
Publication of EA202091015A1 publication Critical patent/EA202091015A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EA202091015A 2017-10-26 2018-10-22 Новый т-клеточный рецептор EA202091015A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1717578.7A GB201717578D0 (en) 2017-10-26 2017-10-26 Novel T-cell receptor
GBGB1806155.6A GB201806155D0 (en) 2017-10-26 2018-04-16 Novel t-cell receptor
PCT/GB2018/053045 WO2019081902A1 (en) 2017-10-26 2018-10-22 NEW LYMPHOCYTE RECEPTOR T

Publications (1)

Publication Number Publication Date
EA202091015A1 true EA202091015A1 (ru) 2020-07-17

Family

ID=60580240

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091015A EA202091015A1 (ru) 2017-10-26 2018-10-22 Новый т-клеточный рецептор

Country Status (17)

Country Link
US (2) US11725039B2 (cg-RX-API-DMAC7.html)
EP (2) EP3700925B8 (cg-RX-API-DMAC7.html)
JP (1) JP7289311B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200078497A (cg-RX-API-DMAC7.html)
CN (1) CN111278855B (cg-RX-API-DMAC7.html)
AU (2) AU2018356944A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020007880A2 (cg-RX-API-DMAC7.html)
CA (1) CA3077635A1 (cg-RX-API-DMAC7.html)
DK (1) DK3700925T3 (cg-RX-API-DMAC7.html)
EA (1) EA202091015A1 (cg-RX-API-DMAC7.html)
ES (1) ES2907819T3 (cg-RX-API-DMAC7.html)
GB (2) GB201717578D0 (cg-RX-API-DMAC7.html)
IL (1) IL274025A (cg-RX-API-DMAC7.html)
MX (1) MX2020004334A (cg-RX-API-DMAC7.html)
PL (1) PL3700925T3 (cg-RX-API-DMAC7.html)
SG (1) SG11202002537WA (cg-RX-API-DMAC7.html)
WO (1) WO2019081902A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717578D0 (en) * 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor
KR20220147583A (ko) * 2020-01-09 2022-11-03 바이오뮤넥스 파마슈티컬스 Mait 및 종양 세포 둘 모두에 결합하는 다중특이적 항체
EP4090969A1 (en) * 2020-01-16 2022-11-23 Universität Basel Mr1 ligands and pharmaceutical compositions for immunomodulation
WO2021250511A1 (ko) * 2020-06-10 2021-12-16 주식회사 유틸렉스 Mr1에 결합하는 t-세포 수용체 및 이의 용도
WO2022099297A1 (en) * 2020-11-04 2022-05-12 Fate Therapeutics, Inc. Multiplexed engineered ipsc and immune effector cells targeting solid tumors
WO2022118043A1 (en) 2020-12-03 2022-06-09 Enara Bio Limited Novel protein-ligand complex
WO2022244876A1 (ja) * 2021-05-20 2022-11-24 慶應義塾 抗腫瘍剤
WO2022248881A1 (en) 2021-05-28 2022-12-01 Enara Bio Limited Novel protein-ligand complex
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
WO2023002204A1 (en) 2021-07-21 2023-01-26 Enara Bio Limited T-cell receptor
KR20230088292A (ko) * 2021-12-10 2023-06-19 주식회사 유틸렉스 MR1 제한적 Panck T 세포 및 이의 제조방법
EP4472742A1 (en) * 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
AU2023248532A1 (en) 2022-04-08 2024-11-21 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI714869B (zh) * 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物
EP3572510B1 (en) 2013-11-21 2022-09-21 Repertoire Genesis Incorporation T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis
AU2018231405B2 (en) * 2017-03-07 2024-02-08 Universität Basel MR1 restricted T cell receptors for cancer immunotherapy
GB201717578D0 (en) * 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor

Also Published As

Publication number Publication date
PL3700925T3 (pl) 2022-05-02
GB201806155D0 (en) 2018-05-30
US20210147506A1 (en) 2021-05-20
SG11202002537WA (en) 2020-05-28
AU2018356944A1 (en) 2020-04-16
AU2024202735A1 (en) 2024-05-30
JP7289311B2 (ja) 2023-06-09
US20200369742A1 (en) 2020-11-26
CA3077635A1 (en) 2019-05-02
CN111278855B (zh) 2024-04-02
IL274025A (en) 2020-06-30
US11725039B2 (en) 2023-08-15
MX2020004334A (es) 2020-08-03
EP4039700A1 (en) 2022-08-10
ES2907819T3 (es) 2022-04-26
EP3700925B1 (en) 2021-12-29
GB201717578D0 (en) 2017-12-13
WO2019081902A1 (en) 2019-05-02
JP2021500406A (ja) 2021-01-07
EP3700925B8 (en) 2022-02-16
DK3700925T3 (en) 2022-04-04
BR112020007880A2 (pt) 2020-10-27
KR20200078497A (ko) 2020-07-01
US11078252B2 (en) 2021-08-03
CN111278855A (zh) 2020-06-12
EP3700925A1 (en) 2020-09-02

Similar Documents

Publication Publication Date Title
MX2020004334A (es) Receptor de celulas t novedoso.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MD4716B1 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
MX2018007406A (es) Anticuerpos anti-lag3 y fragmentos de enlace al antigeno.
PH12018500363A1 (en) Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
MY197324A (en) Adenovirus armed with bispecific t cell activator
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
MY196646A (en) Agonistic Antibodies Specifically Binding Human CD40 And Methods of use
PH12017501166A1 (en) Antibodies to tight
JOP20170170B1 (ar) صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
MX2018003936A (es) Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
EA201990183A1 (ru) Аденовирус, вооруженный биспецифичным активатором т-клеток (bite)
EA201791560A1 (ru) Порошковый состав для интраназального введения для лечения гипогликемии
EA202091276A1 (ru) Новый гамма дельта т-клеточный рецептор и его лиганд
HK1251481A1 (zh) 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
MY187050A (en) Cancer cell-specific antibody, anticancer agent, and cancer testing method
EA201691225A1 (ru) Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение
MX2021005085A (es) Formulacion de anticuerpo.
MX381617B (es) Conjugados de peptido-curcumina y formulaciones de los mismos.
MX2020005495A (es) Anticuerpo anti-vista y uso del mismo.
EA202090565A1 (ru) Композиции и способы лечения диффузной в-крупноклеточной лимфомы
MX2020013601A (es) Receptores de las celulas t especificos de cancer.
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб